HRP20181757T1 - Kombinirana terapija za liječenje raka dojke - Google Patents

Kombinirana terapija za liječenje raka dojke

Info

Publication number
HRP20181757T1
HRP20181757T1 HRP20181757TT HRP20181757T HRP20181757T1 HR P20181757 T1 HRP20181757 T1 HR P20181757T1 HR P20181757T T HRP20181757T T HR P20181757TT HR P20181757 T HRP20181757 T HR P20181757T HR P20181757 T1 HRP20181757 T1 HR P20181757T1
Authority
HR
Croatia
Prior art keywords
breast cancer
combination therapy
treating breast
treating
therapy
Prior art date
Application number
HRP20181757TT
Other languages
English (en)
Inventor
Jay Harper
Scott Michael Lonning
Frank James Hsu
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of HRP20181757T1 publication Critical patent/HRP20181757T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20181757TT 2010-03-12 2018-10-24 Kombinirana terapija za liječenje raka dojke HRP20181757T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31351510P 2010-03-12 2010-03-12
EP16166917.1A EP3117709B1 (en) 2010-03-12 2011-03-08 Combination therapy for treating breast cancer

Publications (1)

Publication Number Publication Date
HRP20181757T1 true HRP20181757T1 (hr) 2019-01-25

Family

ID=44563812

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160932TT HRP20160932T1 (hr) 2010-03-12 2016-07-22 Kombinirana terapija za liječenje raka dojke
HRP20181757TT HRP20181757T1 (hr) 2010-03-12 2018-10-24 Kombinirana terapija za liječenje raka dojke

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20160932TT HRP20160932T1 (hr) 2010-03-12 2016-07-22 Kombinirana terapija za liječenje raka dojke

Country Status (18)

Country Link
US (3) US8911736B2 (hr)
EP (4) EP3117709B1 (hr)
JP (2) JP5917418B2 (hr)
CY (1) CY1117831T1 (hr)
DK (2) DK3117709T3 (hr)
ES (2) ES2584433T3 (hr)
HK (1) HK1206936A1 (hr)
HR (2) HRP20160932T1 (hr)
HU (2) HUE040107T2 (hr)
LT (1) LT3117709T (hr)
ME (1) ME02464B (hr)
PL (2) PL2835053T3 (hr)
PT (2) PT3117709T (hr)
RS (2) RS57942B1 (hr)
SI (2) SI2835053T1 (hr)
SM (1) SMT201600253B (hr)
TR (1) TR201816180T4 (hr)
WO (1) WO2011112609A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117709B1 (en) * 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
AR095240A1 (es) 2013-03-11 2015-09-30 Genzyme Corp ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS
WO2016094697A2 (en) * 2014-12-10 2016-06-16 The Regents Of The University Of Colorado, A Body Corporate Targeting breast cancer therapy based on stromal subtypes and cd146 composition
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
DK3270823T3 (da) * 2015-03-18 2020-07-13 Med El Elektromedizinische Geraete Gmbh Fiksering af en knogleledende flydende massetransducer
KR102647231B1 (ko) 2018-08-02 2024-03-13 삼성전자주식회사 반도체 소자 및 이의 제조방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US247550A (en) * 1881-09-27 Bakee beos
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1990000194A1 (en) 1988-06-28 1990-01-11 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0502036B1 (en) 1989-11-22 1995-12-20 Genentech, Inc. Latency associated peptide and uses therefor
EP1149908A1 (en) 1991-10-31 2001-10-31 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses thereof
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
DE69228700T2 (de) 1991-12-04 1999-09-09 Jolla Cancer Res Found Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
AU3920693A (en) 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
AU3943793A (en) 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0758452B1 (en) 1994-05-04 2001-11-07 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU2749697A (en) 1996-04-30 1997-11-19 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
EP0956036B1 (en) 1996-10-25 2005-12-14 Ethicon, Inc. Anti-fibrotic agent assay
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
DK1278518T3 (da) * 2000-02-28 2007-01-15 Pfizer Entpr Sarl Synergistisk kombination til behandling af colorektal cancer
KR20060127409A (ko) * 2003-11-13 2006-12-12 제넨테크, 인크. 종양 치료 방법 및 스크리닝 검정
JP4871732B2 (ja) * 2003-12-19 2012-02-08 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
AU2005230848B9 (en) * 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
AR052142A1 (es) 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
HUE042689T2 (hu) 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
EP2164856A1 (en) 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
DE102008002395A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Wirkstoffbeladenes Implantat
EP3117709B1 (en) * 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer

Also Published As

Publication number Publication date
EP2835053A1 (en) 2015-02-11
EP2544541B1 (en) 2014-10-08
EP3406141B1 (en) 2020-10-14
ES2694288T3 (es) 2018-12-19
TR201816180T4 (tr) 2018-11-21
EP3117709B1 (en) 2018-08-01
EP2544541A4 (en) 2013-07-31
DK3117709T3 (en) 2018-11-26
RS54972B1 (sr) 2016-11-30
LT3117709T (lt) 2018-11-26
US8911736B2 (en) 2014-12-16
HRP20160932T1 (hr) 2016-10-07
JP5917418B2 (ja) 2016-05-11
JP6289528B2 (ja) 2018-03-07
ES2584433T3 (es) 2016-09-27
DK2835053T3 (en) 2016-08-15
RS57942B1 (sr) 2019-01-31
US10507242B2 (en) 2019-12-17
ME02464B (me) 2017-02-20
PL3117709T3 (pl) 2019-01-31
EP2835053B1 (en) 2016-04-27
US9539325B2 (en) 2017-01-10
HK1206936A1 (zh) 2016-01-22
US20150086547A1 (en) 2015-03-26
PT2835053T (pt) 2016-07-14
SMT201600253B (it) 2016-08-31
US20170319691A1 (en) 2017-11-09
HUE027831T2 (en) 2016-11-28
CY1117831T1 (el) 2017-05-17
JP2016164174A (ja) 2016-09-08
SI2835053T1 (sl) 2016-09-30
EP2544541A1 (en) 2013-01-16
SI3117709T1 (sl) 2018-12-31
US20130034549A1 (en) 2013-02-07
WO2011112609A1 (en) 2011-09-15
JP2013522210A (ja) 2013-06-13
EP3406141A1 (en) 2018-11-28
PT3117709T (pt) 2018-11-15
HUE040107T2 (hu) 2019-02-28
PL2835053T3 (pl) 2016-12-30
EP3117709A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
IL289300A (en) Combined treatment for cancer
HK1254859A1 (zh) 治療乳腺癌的方法
ZA201205003B (en) Methods for treating breast cancer
HK1201413A1 (en) Treatment of breast cancer
IL243741A0 (en) Anti-angiogenic therapy for the treatment of breast cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
HRP20181757T1 (hr) Kombinirana terapija za liječenje raka dojke
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
IL222958A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
EP2585115A4 (en) ANTICANCER TREATMENT
GB201301168D0 (en) Cancer treatment
GB201020513D0 (en) Cancer therapy
ZA201208905B (en) Cancer therapy method
GB201019034D0 (en) Treatment for tumors